



Sosei today hosted an Investor Day in Tokyo

Tokyo, Japan and London, UK, 14 March 2018 – Sosei Group Corporation (TSE Mothers Index: 4565) (“Sosei” or the “Company”), the world leader in GPCR medicine design and development, today held its Investor Day at the Hotel New Otani in Tokyo.

The Investor Day was hosted by members of Sosei’s senior management team, with a keynote presentation from Dr Richard Henderson, 2017 Nobel Prize winner in Chemistry for his pioneering work in the field of cryo-electron microscopy and a co-founder of Sosei’s wholly-owned subsidiary, Heptares Therapeutics.

Highlights of the Investor Day:

- Peter Bains, Sosei’s CEO, provided an introduction on the company and its strategy to build a global biotech company based on innovative new medicines developed through its partnered and proprietary pipelines, and originating from its world-leading structure-based drug design platform.
- In his keynote presentation, Dr Richard Henderson (MRC Laboratory of Molecular Biology, Cambridge, UK) described cryo-electron microscopy, a technique he pioneered for determining three-dimensional information about protein structures at the near atomic level. This information is expected to improve understanding of the structure and function of proteins under investigation, and thereby advance the design of new drugs targeting specific proteins. Sosei is applying cryo-EM alongside its proprietary platform to study G protein-coupled receptor (GPCR) protein complexes, the insights from which are helping to advance the discovery of potential new medicines.
- Chief R&D Officer Dr Malcolm Weir provided an overview of Sosei’s StaR® technology and its ability to enable GPCR structure-based drug design. Dr Weir also provided an update on Sosei’s wholly-owned GPCR pipeline, including its promising CGRP candidates for migraine, to which it recently regained global rights, and partnered GPCR pipeline programmes with Allergan in Alzheimer’s disease and AstraZeneca in immuno-oncology.
- Chief Medical Officer Dr Tim Tasker provided in depth insight into Sosei’s most advanced wholly owned pipeline programme for its selective M₁ agonist candidate for dementia with Lewy bodies (DLB) in Japan, which subject to regulatory approval, is planned to enter clinical Phase 2 proof-of-concept studies in 2018.

A webcast replay of the Investor Day and selected materials will be made available on the Company’s [website](#).

-Ends-

About Sosei

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company's leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei's additional partners and collaborators include Novartis, Teva, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (ticker: 4565). For more information, please visit <http://www.sosei.com/en/>.

Contact information

Chris Cargill, Head of Investor Relations and Corporate Communications
+44 (0)7912 892 199
ccargill@sosei.com

Harumi Banse, Corporate Communications (Japan)
+81 3 5210 3399
hbanse@sosei.com

Citigate Dewe Rogerson (for International media)
Mark Swallow, David Dible
+44 (0)20 7638 9571
sosei@citigatedewerogerson.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.